Janina E E Tirnitz-Parker
Overview
Explore the profile of Janina E E Tirnitz-Parker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gu L, Zhu Y, Nandi S, Lee M, Watari K, Bareng B, et al.
Nature
. 2025 Jan;
638(8051):E30.
PMID: 39890899
No abstract available.
2.
Gu L, Zhu Y, Nandi S, Lee M, Watari K, Bareng B, et al.
Nature
. 2025 Jan;
637(8045):461-469.
PMID: 39743585
Hepatocellular carcinoma (HCC) originates from differentiated hepatocytes undergoing compensatory proliferation in livers damaged by viruses or metabolic-dysfunction-associated steatohepatitis (MASH). While increasing HCC risk, MASH triggers p53-dependent hepatocyte senescence, which we...
3.
Dwyer B, Tirnitz-Parker J
Trends Endocrinol Metab
. 2024 Aug;
36(3):235-248.
PMID: 39191607
Liver diseases represent a growing global health challenge, and the increasing prevalence of obesity and metabolic disorders is set to exacerbate this crisis. To meet evolving regulatory demands, patient-specific in...
4.
Quantitative comparison of presenilin protein expression reveals greater activity of PS2-γ-secretase
Eccles M, Main N, Carlessi R, Milligan Armstrong A, Sabale M, Roberts-Mok B, et al.
FASEB J
. 2023 Dec;
38(1):e23396.
PMID: 38156414
γ-secretase processing of amyloid precursor protein (APP) has long been of interest in the pathological progression of Alzheimer's disease (AD) due to its role in the generation of amyloid-β. The...
5.
Lai X, Lui S, Lam H, Adachi Y, Sim W, Vasilevski N, et al.
NPJ Precis Oncol
. 2023 Dec;
7(1):136.
PMID: 38102334
Despite the promising antitumor activity of SHP2 inhibitors in RAS-dependent tumours, overall responses have been limited by their narrow therapeutic window. Like with all MAPK pathway inhibitors, this is likely...
6.
Boslem E, Reibe S, Carlessi R, Smeuninx B, Tegegne S, Egan C, et al.
Sci Adv
. 2023 Sep;
9(37):eadh0831.
PMID: 37703359
The incidence of hepatocellular carcinoma (HCC) is rapidly rising largely because of increased obesity leading to nonalcoholic steatohepatitis (NASH), a known HCC risk factor. There are no approved treatments to...
7.
Carlessi R, Denisenko E, Boslem E, Kohn-Gaone J, Main N, Abu Bakar N, et al.
Cell Genom
. 2023 May;
3(5):100301.
PMID: 37228755
Current approaches to staging chronic liver diseases have limited utility for predicting liver cancer risk. Here, we employed single-nucleus RNA sequencing (snRNA-seq) to characterize the cellular microenvironment of healthy and...
8.
Xavier das Neves R, Yamashita A, Riccardi D, Kohn-Gaone J, Camargo R, Neto N, et al.
J Cachexia Sarcopenia Muscle
. 2023 May;
14(4):1621-1630.
PMID: 37177862
Background: Cachexia is a wasting syndrome associated with systemic inflammation and metabolic disruption. Detection of the early signs of the disease may contribute to the effective attenuation of associated symptoms....
9.
Abu Bakar N, Carlessi R, Gogoi-Tiwari J, Kohn-Gaone J, Williams V, Falasca M, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980694
Chronic pancreatitis increases the risk of developing pancreatic cancer through the upregulation of pathways favouring proliferation, fibrosis, and sustained inflammation. We established in previous studies that the ligand tumour necrosis...
10.
Cabanes-Creus M, Navarro R, Liao S, Scott S, Carlessi R, Roca-Pinilla R, et al.
Mol Ther Methods Clin Dev
. 2023 Jan;
28:220-237.
PMID: 36700121
Recent clinical successes have intensified interest in using adeno-associated virus (AAV) vectors for therapeutic gene delivery. The liver is a key clinical target, given its critical physiological functions and involvement...